STOCK TITAN

Viridian Therapeutics, Inc. - VRDN STOCK NEWS

Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from thyroid eye disease (TED). The company's primary product candidate, VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) that holds promise for treating TED, a rare and debilitating condition.

Viridian Therapeutics leverages cutting-edge science and a deep understanding of disease biology to advance its therapeutic candidates. Their lead candidate, VRDN-001, is aimed at mitigating the symptoms of TED, which include inflammation, pain, and vision impairment. By targeting IGF-1R, VRDN-001 has the potential to offer a novel treatment option for patients who currently have limited choices.

The company’s commitment to scientific excellence is reflected in its rigorous clinical trials and strategic partnerships. Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies. These collaborations provide valuable resources and expertise, helping to accelerate the progress of their drug candidates.

In terms of financial health, Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs. The company continuously explores opportunities to bolster its financial stability through strategic partnerships and potential equity financing. Viridian's prudent financial management ensures that it can sustain its operations and continue its mission to bring transformative therapies to patients in need.

Viridian's focus on thyroid eye disease addresses a significant unmet medical need. The company aims to develop treatments that improve the quality of life for patients suffering from this challenging condition. By pursuing innovative approaches and maintaining a patient-centric mindset, Viridian is making meaningful strides in the field of biopharmaceuticals.

Stay updated with the latest news and developments from Viridian Therapeutics as they progress in their mission to deliver groundbreaking therapies for underserved patient populations.

Rhea-AI Summary
Viridian Therapeutics, Inc. will present clinical and preclinical data on its pipeline candidates for the treatment of thyroid eye disease (TED) at the AAO 2023 Annual Meeting. The company will highlight VRDN-001, a full antagonist antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), including preliminary clinical results from a Phase 1/2 study. VRDN-001 is currently in Phase 3 clinical studies for active and chronic TED. Viridian will also present preclinical data for VRDN-003, a half-life extended antibody targeting IGF-1R. VRDN-003 is in a Phase 1 clinical study in healthy volunteers. The company expects to select its lead subcutaneous IGF-1R program by year end 2023 and release VRDN-001 Phase 3 topline results in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
none
-
Rhea-AI Summary
Viridian Therapeutics appoints Stephen Mahoney as President and CEO. The company remains on track with its thyroid eye disease programs and expects to select a subcutaneous program by year-end 2023. They also disclose a portfolio of FcRn inhibitors for autoimmune diseases. A private placement will provide $185 million in funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
management
-
Rhea-AI Summary
Viridian Therapeutics and Ypsomed AG have signed a supply agreement for Ypsomed's YpsoMate 2.25 autoinjector pen device. The device will be customized and supplied to support Viridian's development of subcutaneous therapy candidates for the treatment of thyroid eye disease (TED). This agreement will potentially expand the TED medicines market and offer more convenience to caregivers and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
none
Rhea-AI Summary
Sarah Gheuens, CMO and Head of R&D of Agios Pharmaceuticals, joins Viridian Therapeutics' Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
management
-
Rhea-AI Summary
Viridian Therapeutics announces presentations on pipeline candidates for thyroid eye disease at upcoming medical meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
Rhea-AI Summary
Viridian Therapeutics, Inc. (Nasdaq: VRDN) announces the approval of non-qualified stock options for new employees, granted as an inducement for entering employment. The options total 140,000 shares with a four-year vesting period, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
none

FAQ

What is the current stock price of Viridian Therapeutics (VRDN)?

The current stock price of Viridian Therapeutics (VRDN) is $22.84 as of November 4, 2024.

What is the market cap of Viridian Therapeutics (VRDN)?

The market cap of Viridian Therapeutics (VRDN) is approximately 1.7B.

What does Viridian Therapeutics, Inc. do?

Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease, with a primary focus on their product candidate VRDN-001.

What is VRDN-001?

VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody being developed by Viridian Therapeutics for the treatment of thyroid eye disease.

What condition does Viridian Therapeutics aim to treat?

Viridian Therapeutics is focused on developing treatments for thyroid eye disease, a rare and debilitating condition.

How does VRDN-001 work?

VRDN-001 targets the insulin-like growth factor-1 receptor (IGF-1R) to potentially reduce inflammation, pain, and vision impairment associated with thyroid eye disease.

Who are Viridian Therapeutics' partners?

Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies.

What is the financial condition of Viridian Therapeutics?

Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs and explores opportunities for strategic partnerships and equity financing.

Why is thyroid eye disease a focus for Viridian Therapeutics?

Thyroid eye disease represents a significant unmet medical need with limited treatment options, and Viridian aims to develop therapies that improve the quality of life for these patients.

How can I stay updated on Viridian Therapeutics' progress?

You can stay updated by following the latest news and developments from Viridian Therapeutics as they advance their clinical programs and partnerships.

Where is Viridian Therapeutics listed?

Viridian Therapeutics is listed on the NASDAQ stock exchange under the ticker symbol VRDN.

What makes Viridian Therapeutics' approach unique?

Viridian Therapeutics leverages in-depth disease biology knowledge and cutting-edge science to develop innovative therapies, particularly targeting the IGF-1R pathway for thyroid eye disease.

Viridian Therapeutics, Inc.

Nasdaq:VRDN

VRDN Rankings

VRDN Stock Data

1.74B
76.36M
0.01%
96.04%
12.82%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM